The AMS Group of companies specialise in the design, development, manufacture and distribution of novel, high performance advanced wound care products, surgical dressings and medical grade materials as well as medical adhesives and sutures for closing and sealing tissue.
AMS Group plc was founded in 1991 in Winsford, Cheshire, U.K. It was originally set up to offer R&D, manufacturing and Sales & Marketing capabilities providing advanced wound care products for major healthcare companies. In 2002 the Group acquired Advanced Medical Solutions (Plymouth) Limited (formerly MedLogic Global Ltd) based in Plymouth, Devon. This provided the Group with technology in cyanoacrylate based medical adhesives and a direct U.K. sales force. Advanced Medical Solutions (Plymouth) Limited and Advanced Medical Solutions Limited completed an entity merger in June 2018 and both now operate under Advanced Medical Solutions Limited.
In October 2009, following a successful joint venture with Recticel, the Group acquired the Netherlands based hydrophilic polyurethane manufacturer Corpura B.V. (now known as Advanced Medical Solutions B.V.).
In 2011 the Group further expanded acquiring RESORBA Wundversorgung GmbH & Co KG (now known as RESORBA Medical GmbH), a long established wound care and wound closure business, providing suture and collagen technologies, headquartered in Germany with direct sales in Germany, the Czech Republic and Russia.
In 2019, the Group acquired Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform. Sealantis is an Israeli-based medical device company with a patent-protected alga-mimetic sealants technology platform with a wide range of potential surgical indications under development. Its two most advanced surgical sealant products are Seal-G, an open surgery device already CE marked for reinforcement of the staple / suture line to minimise anastomotic leaks following gastrointestinal surgery, and Seal-G MIST (Minimally Invasive Spray Technology) the equivalent laparoscopic device for the same indication but performed through key hole surgery.
AMS is listed on the Alternative Investment Market (AIM).
Today the Group has a global customer base, operates out of 7 locations and employs over 600 people
The AMS Group operates through two Divisions each responsible for their respective sales, marketing and Research and Development (R&D) activities. Both Divisions focus on a different strategic route to market.
Our products and materials are sold in over 70 countries worldwide.
The AMS Group has six manufacturing facilities, six sales offices in Europe, and a sales team operating in the United States. The Group’s headquarters are located in the U.K.
- Winsford, U.K.: HQ: Advanced Wound Care manufacturing, R&D, Sales & Marketing
- Plymouth, U.K.: Tissue adhesives manufacturing, R&D, Sales & Marketing
- Etten Leur, the Netherlands: Bulk foam roll-stock manufacturing, Sales & Marketing
- Nuremberg, Germany: RESORBA® Collagen and Haemostats manufacturing, R&D, Sales & Marketing
- Domazlice, the Czech Republic: RESORBA® Sutures manufacturing & Sales
- Neustadt, Germany: RESORBA® Sutures manufacturing
- Moscow, Russia: Sales